Pulmonary hypertension
Not yet recruitingPhase 3 Trial Evaluating Inhaled Mosliciguat for Safety, Efficacy, and Exercise Capacity in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease
Phase 3 Trial Evaluating Inhaled Mosliciguat for Safety, Efficacy, and Exercise Capacity in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease
- Disease:Pulmonary hypertension
- Substances:Mosliciguat
Belgium- Participants:18–64 years · 65+ years
- Substances:Mosliciguat
- Sponsor:Pulmovant Inc.






